Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-amplified colorectal cancer, drawn from the whole corpus: 29 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised evidence yet for HER2 blockade in first line.
RAS co-mutation blunts dual HER2 blockade and the best option for those patients is unclear.
Optimal sequence of tucatinib-trastuzumab and trastuzumab deruxtecan is untested.
HER2 mutations without amplification have no proven therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
ORR 37.
A milestone in how this cancer is treated.
Phase 2 ORR 38.
A milestone in how this cancer is treated.